While most sectors see their constituents moved by more benign news such as earnings reports, dividend increases/decreases, share repurchases, insider buying/selling and scores of other typical headlines, that’s just not the case with most biotechnology stocks. When you get down to it, most biotech stocks, particul. Read More --